---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-049683"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-09-25T23:59:59+00:00"
generated_at: "2026-06-10T09:16:51.496449+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Pharma raises $250M in PIPE financing led by Qatar Investment Authority

## Summary
- Issues 9,167,723 shares at $27.27/share (Sept 22 close); gross proceeds ~$250M.
- Financing led by QIA, with participation from four large US investment management firms.
- Proceeds to fund acoramidis launch, Phase 3 readouts in achondroplasia, LGMD2I, ADH1, and general corporate purposes.
- PIPE expected to close Sept 27, 2023, subject to customary conditions.
- Company also exploring additional less dilutive financing options to optimize cost of capital.

## SEC filing metadata
- accession: 0000950170-23-049683
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017023049683/0000950170-23-049683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017023049683/bbio-20230925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-049683
- JSON: https://secwatch.observer/filing/0000950170-23-049683.json
- Plain text: https://secwatch.observer/filing/0000950170-23-049683.txt

## Key facts
- Material Agreements
  BridgeBio Pharma, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $250 million (effective 2023-09-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $250 million
  - Effective: 2023-09-25
  source text: On September 25, 2023, BridgeBio Pharma, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of 9,167,723 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $27.27 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000095017023049683/0000950170-23-049683-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.